Is D-amphetamine making a comeback as a weight-loss drug?



From Ergo Log

There may be a medicine that helps obese people to lose excess weight effectively. No, it’s not an obscure high-tech drug with an unpronounceable name that does interesting things to lab rats. According to researchers at the University of Sydney in Australia, the ancient D-amphetamine is a tried-and-tested and extremely effective weight-loss drug.


The amphetamine that does the rounds in the illegal drugs world is a mixture of two substances: D- and L-amphetamine. Both D- and L-amphetamine are stimulants. They imitate the effect of neurotransmitters such as dopamine and noradrenalin. Because D-amphetamine circulates through the body for longer than L-amphetamine after intake D-amphetamine has a stronger effect than L-amphetamine.

Nowadays amphetamine is a street drug, but in the 1960s doctors prescribed substances such as Benzedrine as a matter of course for people who complained of fatigue or listlessness. Benzedrine contains a mix of D and L amphetamine, just like the amphetamine found in the drugs world.

When it became clear that amphetamine is addictive [Br Med J. 1962 Jul 7;2(5296):40-3.], causes heart attacks and strokes and on top of that can lead to psychoses [Arch Gen Psychiatry. 1972 Feb;26(2):97-100.], governments all over the world banned the substance.


But before that happened doctors did experiments with preparations like Benzedrine on people with serious weight problems. According to an article published in 1947, in a period of 8 months, men could lose 13 kg and women 11 kg by taking amphetamines. [Am J Dig Dis. 1947 May;14(5):153-62.] The main reason for this is that amphetamine suppresses appetite.


Nowadays doctors occasionally prescribe amphetamine for adults with ADHD. In 2009 Canadian researchers reported that overweight people suffering from ADHD who had been prescribed amphetamine lost 15 kg weight in 15 months. [Int J Obes (Lond). 2009 Mar;33(3):326-34.]


No one disputes that the use of amphetamine is risky, write the Australian researchers in Frontiers in Endocrinology. But obesity is dangerous too and the amount of overweight people continues to increase. The need for a substance that can help fight obesity is becoming more and more urgent. That’s why the researchers did a small trial to look at the slimming effect of D-amphetamine in obese people.


Is D-amphetamine making a comeback as a weight-loss drug?
The Australians gave 14 subjects, who had an average weight of 102.4 kg, increasing doses of D-amphetamine over a period of six months. The subjects started on a dose of 5 mg D-amphetamine with breakfast and a similar dose with lunch. Every two weeks the daily dose was increased by 10 mg, until the subjects were taking two doses of 30 mg every day. If a subject developed serious side effects the dose was taken back one level.


During the course of amphetamine the subjects tried to eat more healthily and to get more exercise and at the end of the period they were advised to continue these habits.


In the six months that the subjects took D-amphetamine they lost 10.6 kg. In the six months after the experiment they gained 4.5 kg again. The researchers didn’t look at the effect on body composition so they don’t know how much muscle mass the subjects lost as a result of taking D-amphetamine.

“In the search for obesity treatment, the amphetamines have been largely overlooked. The argument that these are too dangerous is implausible as they have continued to be prescribed for ADHD”, the researchers summarised. “Increasing the therapeutic indications for dexamphetamine would certainly lead to more availability and, therefore, more potential for abuse.”


“However, we believe that there are a large number of individuals who are struggling to lose weight and would use dexamphetamine responsibly. Careful participant selection, close observation, and relatively short treatment period would minimize the opportunity to abuse the drug and would also reduce the risks of long-term cardiovascular complications.”


“Our findings need confirmation with a larger, double-blind placebo-controlled study.”


Front Endocrinol (Lausanne). 2015 Feb 9;6:14.




Be Sociable, Share!

Leave a Reply

* Copy This Password *

* Type Or Paste Password Here *